Trial Profile

A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary) ; Imatinib
Indications Gastrointestinal stromal tumours
Focus Therapeutic Use
Acronyms ALT GIST

Most Recent Events

19 Aug 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.
29 Jun 2024 This trial has been completed in Slovakia, according to European Clinical Trials Database record
26 Jun 2024 This trial has been completed in Netherlands , according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com